Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liesbeth Lewi has a total of 913 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Placental Histological Lesions in Monochorionic Twins With Selective Fetal Growth Restriction Versus Growth‐Restricted Singletons: A Cohort Study

    by Jip A. Spekman, Sophie G. Groene, Anne T. R. Noll, Femke Slaghekke, Chiara C. M. M. Lap, Angélique van Dam, Liesbeth Lewi, Lotta Herling, E. J. T. Verweij, Monique C. Haak, et al.

    Objective: To determine the prevalence of placental histological lesions in the smaller twin's placental territory in monochorionic (MC) twins complicated by selective fetal growth restriction (sFGR), and compare it to FGR singletons. Design: Cohort study with 1:1 comparison. Setting: Leiden University Medical Center, The Netherlands. Population: Forty‐four MC twin placentas with sFGR and 44 FGR singleton placentas, histologically evaluated between 2020 and 2025. Methods: FGR was defined as birthweight < 10th percentile. sFGR was defined as birthweight discordance ≥ 20% between twins and birthweight < 10th percentile for the smaller twin. Placental parenchyma was examined using Amsterdam Consensus Statement criteria for maternal vascular malperfusion (MVM), fetal vascular malperfusion (FVM), and acute and chronic inflammation. Analyses of placental lesions were adjusted for gestational age at diagnosis of (s)FGR. Main Outcome Measures: Prevalence of histological lesions. Results: Median gestational age at birth was 37.1 weeks (IQR 32.0–38.1) for FGR singletons and 32.3 weeks (IQR 30.1–35.0) for sFGR twins ( p < 0.001). FVM was more common in smaller twins than sFGR singletons (45% versus 16%; OR 3.7 (95% CI: 1.0–13.2); p = 0.046), alongside a higher prevalence of abnormal cord insertions (84% versus 21%; p < 0.001). MVM prevalence was similar between smaller twins and FGR singletons (73% versus 75%; OR 0.8 (95% CI: 0.2–2.9); p = 0.779), as was chronic inflammation (27% versus 34%; OR 0.7 (95% CI: 0.2–2.3); p = 0.549). Conclusions: The smaller twin's placental territory in sFGR showed lesions consistent with placental insufficiency, with prevalences of MVM and chronic inflammation comparable to FGR singletons and increased prevalence of FVM. These findings suggest that placental insufficiency may be involved in the pathophysiology of sFGR alongside unequal sharing.

  • Twin pregnancy

    by Asma Khalil, Jeffrey M. Craig, Stephanie Ernst, Liesbeth Lewi, Enrico Lopriore, Nir Melamed, Christiaan Monden, Roberto Romero, Daniel L. Rolnik, Nancy L. Segal, et al.

  • Open Access

    Incidence of pre‐eclampsia in triplet pregnancies with and without embryo reduction

    by G. Yerlikaya‐Schatten, A. Wright, S. Kristensen, O. B. Petersen, P. Chaveeva, A. J. Vivanti, N. Persico, F. S. Molina, L. Lewi, E. Litwinska, et al.

    Objective: To determine the risk of pre‐eclampsia (PE) in triplet pregnancies, with and without embryo reduction, compared to singleton and twin pregnancies. Methods: This was a retrospective multicenter study of triplet pregnancies with three live, phenotypically normal fetuses at the 11–13‐week scan and a gestational age at delivery of ≥ 24 weeks. The competing‐risks model was used to determine the distribution of gestational age at delivery with PE in each type of triplet pregnancy, which was compared to datasets from 1169 twin pregnancies and 61 174 singleton pregnancies from previous cohorts. The relative risks of PE with delivery < 37, < 34 and < 32 weeks' gestation for non‐reduced and reduced triplet pregnancies, in comparison with twin and singleton pregnancies, were determined. Results: Overall, 1020 triplet pregnancies were included, of which 456 had expectant management, 468 were reduced to twin pregnancies and 96 were reduced to singleton pregnancies. The incidence of PE with delivery < 37 weeks' gestation was 9.9% for non‐reduced triplet pregnancies, 9.8% for triplet pregnancies reduced to twins, 2.1% for triplet pregnancies reduced to singleton, 7.0% for twin pregnancies and 0.8% for singleton pregnancies. The incidence of PE with delivery < 34 weeks was 7.2% for non‐reduced triplets, 4.1% for triplets reduced to twins, 0% for triplets reduced to singleton, 0.9% for twins and 0.4% for singletons. In comparison with singleton pregnancies, for non‐reduced triplets, the relative risks for PE with delivery < 37 and < 34 weeks were 12.3 (95% CI, 9.1–16.3) and 20.6 (95% CI, 14.4–29.2), respectively. The respective values for triplet pregnancies reduced to twins were 12.2 (95% CI, 9.1–16.2) and 11.6 (95% CI, 7.3–18.2), and for triplet pregnancies reduced to singleton they were 2.6 (95% CI, 0.7–9.1) and 0.0 (95% CI, 0.0–11.0). In comparison with twin pregnancies, for non‐reduced triplets the relative risks for PE with delivery < 37 and < 34 weeks were 1.4 (95% CI, 1.0–2.0) and 7.7 (95% CI, 4.0–14.9), respectively. The respective values for triplets reduced to twins were 1.4 (95% CI, 1.0–2.0) and 4.3 (95% CI, 2.1–8.9). For a given set of maternal characteristics and medical history, a non‐reduced triplet pregnancy was estimated to deliver with PE, on average, 14.5 weeks earlier than would a singleton pregnancy. Triplet pregnancies reduced to twins were estimated to deliver with PE 12.7 weeks earlier, and those reduced to singleton 6.5 weeks earlier, than would comparable singleton pregnancies. Conclusion: Non‐reduced triplet pregnancies have a 21‐fold and 8‐fold higher risk of delivery with PE at < 34 weeks' gestation compared with singleton and twin pregnancies, respectively. In triplet pregnancies reduced to twins, the relative risk of PE < 34 weeks is 4‐fold higher than that in twin pregnancies, whereas in triplet pregnancies reduced to singleton, the risk is similar to that of singleton pregnancies. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

  • Nonrandom distribution of arteriovenous anastomoses in monochorionic twin placentas

    by Amira Steenbergen, Jip Anne Spekman, Alexandre J. Vivanti, Enrico Lopriore, Francesca M. Russo, Johannes M. van der Merwe, Roland Devlieger, Femke Slaghekke, Liesbeth Lewi

  • Effect of right‐ vs left‐sided congenital diaphragmatic hernia and duration of tracheal occlusion on longitudinal lung‐size changes

    by K. Watananirun, D. Basurto, R. J. Martinez‐Portilla, O. Gomez, A. M. L. F. Vargas, F. M. Russo, L. De Catte, L. Lewi, R. Devlieger, C. F. A. Peralta, et al.

    Objectives: To describe patterns of lung‐size changes after fetoscopic endoluminal tracheal occlusion (FETO) in cases of right‐sided congenital diaphragmatic hernia (RCDH) compared with in cases of left‐sided congenital diaphragmatic hernia (LCDH), and the association between lung growth and the duration of occlusion. Methods: This was a longitudinal observational cohort study conducted at three fetal surgery centers (UZ Leuven, Leuven, Belgium; BCNatal, Barcelona, Spain; The Heart Hospital of São Paulo, São Paulo, Brazil) using similar prenatal management protocols. Inclusion criteria were pregnant women with a fetus with isolated congenital diaphragmatic hernia (CDH) that underwent FETO between July 2002 and October 2021 with a minimum of two measurements of the fetal observed‐to‐expected lung‐to‐head ratio (o/e‐LHR) (one before and at least one after FETO) available. The o/e‐LHR was used as a proxy for fetal lung size. Other variables were the side of the defect and gestational age at FETO and at balloon removal. Multilevel analysis was used to model longitudinal changes in fetal lung size. The changes in o/e‐LHR during the occlusion period (∆ o/e‐LHR (%), referred to as ‘change in absolute lung size’) were calculated and corrected for baseline measurement (‘proportional’ lung size change (%)) and expressed as a function of the duration of occlusion (referred to as proportional lung growth rate (%/day)). A structural break point was used to identify a significant change in proportional lung growth rate during the occlusion period. Patterns of proportional lung‐size change and proportional lung growth rate were compared between RCDH and LCDH using Student's t ‐test. Results: We reported 1026 o/e‐LHR measurements in 338 fetuses (RCDH, n = 73; LCDH, n = 265). The pattern of lung growth after FETO was comparable in cases of RCDH and LCDH, with a sharp increase in size immediately after occlusion (60% vs 50%, respectively, compared with baseline measurements), followed by a slower increase over the remainder of the observation period. Overall, over the 6‐week period, lung size in cases of RCDH expanded by 140% compared with baseline, while in cases of LCDH lung size expanded by 100% ( P < 0.001). The pattern of proportional lung growth rate was also similar, starting with a high growth rate at day 2 after FETO, followed by slower but persistent growth. In cases of RCDH, lungs had a slower initial growth rate compared with LCDH (13.11%/day (95% CI, 3.72–22.52%/day) vs 15.67%/day (95% CI, 6.69–24.66%/day); P < 0.001). The proportional growth rates over the 6‐week period were comparable between RCDH and LCDH (2.91%/day vs 1.84%/day; P = 0.081). The structural break point showed a significant change in growth rate at day 5 and day 31 after FETO for cases of LCDH and day 8 after FETO for cases of RCDH. Conclusion: There are measurable differences in proportional lung growth rates after FETO between cases of RCDH and LCDH. However, the pattern of lung‐size changes parallel each other, with an initial fast growth rate that dropped to a lower but persisting rate later in the occlusion period. The continued increase in fetal lung size observed after FETO supports previous observations that the duration of occlusion may influence the treatment response in CDH. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.

  • Open Access

    Predicting outcomes in selective fetal growth restriction of monoChOrioNic Twins: an inteRnAtional observational cohort STudy protocol (CONTRAST study)

    by Anne Noll, Ali Javinani, Femke Slaghekke, Monique C Haak, Jeanine van Klink, Lotte Van der Meeren, Enrico Lopriore, Francesca Russo, Michael Aertsen, Alireza Shamshirsaz, et al.

    Introduction Selective fetal growth restriction (sFGR) is a major cause of perinatal morbidity and mortality in monochorionic diamniotic (MCDA) twin pregnancies. Current management relies on umbilical artery Doppler patterns in the smaller twin. These patterns are, however, inconsistent and do not represent a reliable severity scale, complicating clinical decision-making and parental counselling. This study aims to improve risk stratification by identifying predictors of adverse outcomes, while also evaluating the pathophysiology and multi-organ impact of sFGR in early childhood. Methods and analysis This is a prospective, international, multicentre cohort study conducted in six tertiary fetal medicine centres with expertise in complicated twin pregnancies. Recruitment began in March 2023 and will continue until December 2026, targeting 274 MCDA twin pairs with complete follow-up to develop a prediction model for adverse perinatal outcomes in sFGR at the time of diagnosis. Standardised data collection includes serial ultrasound examinations, advanced fetal imaging (cardiac, cerebral and 3D volumetric), fetal brain MRI and detailed placental phenotyping. Maternal and parental well-being are assessed during pregnancy and after birth. Neurodevelopmental outcome is evaluated up to 2 years after birth using validated tools. The statistical analysis plan includes predictive modelling with internal validation. Ethics and dissemination The study has been approved by the ethical review boards of all participating centres. Findings will be disseminated through peer-reviewed publications, international conferences and engagement with clinical guideline committees. Trial registration number NCT05952583.


  • Hemoglobin Bart’s Disease and the Agrinio Mutation: A Case Report of Successful Fetal Intervention

    by Kobe Haenen, Emma Van Den Eede, Jeroen Breckpot, Veerle Labarque, Gunnar Naulaers, Liesbeth Lewi, Roland Devlieger

    Introduction: Hemoglobin Bart’s hydrops fetalis syndrome (BHFS) is the most severe form of α-thalassemia, typically caused by homozygous deletion of α-globin genes. However, rare non-deletional variants, such as Hemoglobin (Hb) Agrinio, can also produce a lethal phenotype. Case Presentation: We report a case of homozygous Hb Agrinio (HBA2:c.89T>C, p.Leu30Pro) diagnosed prenatally in a fetus of Bulgarian origin presenting with hydrops and severe anemia at 23 weeks of gestation. Following diagnosis, the pregnancy was managed with five intrauterine transfusions, resulting in resolution of hydrops and prolongation of pregnancy to term. The neonate was delivered at 37+3 weeks, required transient respiratory and cardiovascular support, and remains clinically stable at 3 months of age under regular transfusion therapy. Conclusion: To our knowledge, this is only the second reported case of BHFS resulting from homozygous Hb Agrinio successfully managed with intrauterine transfusions, and uniquely, the first to achieve term delivery. This case highlights the importance of considering unstable α-globin variants in the differential diagnosis of unexplained fetal hydrops in an at-risk population. Early diagnosis and timely intrauterine transfusions can significantly improve the perinatal outcomes in these cases.

  • Open Access

    Comparison of Insertion Difficulties and Performance of Thoracoamniotic Shunts for Fetal Hydrothorax

    by Tess T. Treurniet, Nimrah Abbasi, Greg Ryan, Ruben S. G. M. Witlox, Femke Slaghekke, Lone Nikoline Nørgaard, Karin Sundberg, Peter Lindgren, Sverker Ek, Basky Thilaganathan, et al.

    Objective: This study compared insertion difficulties, shunt failure, reintervention rates, maternal adverse events, and neonatal outcomes among different shunt types used in fetal hydrothorax. Method: A retrospective multicenter cohort study (2012–2022) was conducted across 12 international centers. The primary outcome was the occurrence of complications, classified as insertion difficulties and shunt failure (dislocation, occlusion, or unexplained shunt failure). Secondary outcomes included reintervention rates, maternal complications, and neonatal survival. Results: Among 349 cases, 345 were included in the analysis of the outcome measures. Rodeck shunts had significantly fewer complications (19.5%) compared to Somatex (38.3%, OR 2.53, p = 0.016) and Harrison shunts (50.0%, OR 3.82, p < 0.001). Somatex shunts had the highest rate of incorrect positioning (16%), while dislocation was most frequent with Harrison shunts (31.1%). Reintervention rates were lowest for Rodeck (12.1%) and highest for Harrison (32.2%). Maternal body mass index, fetal hydrops, laterality and year of shunt placement did not significantly influence complication rates. No significant differences in live birth rates or gestational age at delivery were observed. Conclusions: The Rodeck shunt was associated with fewer insertion difficulties, better shunt performance and lower reintervention rates. There was no difference in perinatal survival among the three shunt types.